title: Patients > or = age 40 years undergoing autologous or allogeneic BMT have regimen-related mortality rates and event-free survivals comparable to patients < age 40 years.
abstract: To evaluate the safety and efficacy of marrow transplantation for older adults, the regimen-related mortality and event-free survival for patients > or = 40 years were compared with those for patients < 40 years. Of 148 consecutive patients receiving autotransplants for lymphoma or Hodgkin's disease, 70 were < 40 years and 78 were > or = 40 years at the time of transplant, including 40 who were > or = 50 years and 12 who were > or = 60 years. Eleven patients (16%) in the younger age group died from transplant-related complications compared with 4 (5%) in the older age group. The 4-year actuarial event-free survivals (EFS) for the younger and older age groups were 43% and 48%, respectively. After adjustment for covariates with prognostic significance, older age was marginally associated with improved event-free survival (P = 0.08). Of 92 consecutive patients undergoing allogeneic BMT during the same period, 62 patients were < 40 years and 30 patients were > or = 40 years, including 8 patients > or = 50 years, and 1 patient > 60 years. Non-relapse mortality (including deaths from GVHD) occurred in 28 of the younger patients (45%) and 9 of the older patients (30%). The 3-year actuarial EFS for the younger patients was 26% vs. 56% for the patients > or = 40 years (P = 0.057). However, this difference was mainly due to the higher proportion of patients with CML and early-stage leukemia in the older age group.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Hematology Unit, University of Rochester Medical Center, NY 14642, USA.
authors.forename: A P
authors.initials: AP
authors.lastname: Rapoport
authors.forename: J F
authors.initials: JF
authors.lastname: DiPersio
authors.forename: B A
authors.initials: BA
authors.lastname: Martin
authors.forename: R E
authors.initials: RE
authors.lastname: Duerst
authors.forename: P A
authors.initials: PA
authors.lastname: Kouides
authors.forename: J L
authors.initials: JL
authors.lastname: Liesveld
authors.forename: C N
authors.initials: CN
authors.lastname: Abboud
authors.forename: C H
authors.initials: CH
authors.lastname: Packman
authors.forename: S W
authors.initials: SW
authors.lastname: Eberly
authors.forename: M
authors.initials: M
authors.lastname: Sherman
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D016026:Bone Marrow Transplantation; D002648:Child; D018572:Disease-Free Survival; D005260:Female; D006689:Hodgkin Disease / Q000401:mortality / Q000628:therapy*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015996:Survival Rate; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous